Graviola Pharmacology Hub
A research index of the pharmacology, safety, and formulation engineering writeups on Annona muricata (graviola) maintained by Labisan. Labisan produces a 22 to 1 fruit water extract sold under the brand name Labisan Graviola Capsules.
The graviola literature is messy: over 500 acetogenins have been isolated, the in vitro antiviral data is whole-extract not isolate-level, and the 1999 Caparros-Lefebvre Caribbean atypical parkinsonism cluster set a real safety signal that most consumer marketing ignores. This hub indexes Labisan’s writeups on what the literature actually says.
Mechanism research
- Is there a specific anti-herpes acetogenin in graviola? An honest pharmacology answer
- NOX, HIF-1 alpha, and graviola: gas pedal, war mode, brake pedal
- Graviola antioxidant and flavonoid profile: quercetin, kaempferol, gallic acid
- Graviola, chronic stress, and immune resilience
- Graviola sleep recovery pharmacology
Safety and dose engineering
- Annonacin and the Caribbean Parkinson signal: why the Labisan safety architecture matters
- Graviola fruit extract vs leaf extract: the safety choice that actually matters
- Graviola one year on, one year off cycling protocol
- The 8000mg daily graviola dose: three-capsule protocol explained
- Why the HPMC capsule shell matters more than the active inside
Comparison studies
- Graviola vs acyclovir: HSV comparison
- Graviola vs lysine for cold sores and herpes
- Melissa officinalis plus graviola: 98 percent HSV suppression vs 90 percent graviola alone
- Graviola prevention vs early outbreak: the itching window protocol